1 Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain.
2 Intensive Care Unit, Hospital Universitario de Burgos, Burgos, Spain.
J Intensive Care Med. 2019 Sep;34(9):740-750. doi: 10.1177/0885066617711882. Epub 2017 Jun 26.
To determine the epidemiology and outcome of severe sepsis and septic shock after 9 years of the implementation of the Surviving Sepsis Campaign (SSC) and to build a mortality prediction model.
This is a prospective, multicenter, observational study performed during a 5-month period in 2011 in a network of 11 intensive care units (ICUs). We compared our findings with those obtained in the same ICUs in a study conducted in 2002.
The current cohort included 262 episodes of severe sepsis and/or septic shock, and the 2002 cohort included 324. The prevalence was 14% (95% confidence interval: 12.5-15.7) with no differences to 2002. The population-based incidence was 31 cases/100 000 inhabitants/year. Patients in 2011 had a significantly lower Acute Physiology and Chronic Health Evaluation II (APACHE II; 21.9 ± 6.6 vs 25.5 ± 7.07), Logistic Organ Dysfunction Score (5.6 ± 3.2 vs 6.3 ± 3.6), and Sequential Organ Failure Assessment (SOFA) scores on day 1 (8 ± 3.5 vs 9.6 ± 3.7; < .01). The main source of infection was intraabdominal (32.5%) although microbiologic isolation was possible in 56.7% of cases. The 2011 cohort had a marked reduction in 48-hour (7% vs 14.8%), ICU (27.2% vs 48.2%), and in-hospital (36.7% vs 54.3%) mortalities. Most relevant factors associated with death were APACHE II score, age, previous immunosuppression and liver insufficiency, alcoholism, nosocomial infection, and Delta SOFA score.
Although the incidence of sepsis/septic shock remained unchanged during a 10-year period, the implementation of the SSC guidelines resulted in a marked decrease in the overall mortality. The lower severity of patients on ICU admission and the reduced early mortality suggest an improvement in early diagnosis, better initial management, and earlier antibiotic treatment.
在实施《拯救脓毒症运动》(SSC)9 年后,确定严重脓毒症和脓毒性休克的流行病学和结局,并建立一个死亡率预测模型。
这是一项前瞻性、多中心、观察性研究,于 2011 年在 11 个重症监护病房(ICU)网络中进行了 5 个月。我们将研究结果与 2002 年在同一 ICU 进行的研究进行了比较。
当前队列包括 262 例严重脓毒症和/或脓毒性休克发作,而 2002 年队列包括 324 例。患病率为 14%(95%置信区间:12.5-15.7),与 2002 年无差异。基于人群的发病率为 31 例/100000 居民/年。2011 年患者的急性生理学和慢性健康评估 II 评分(APACHE II;21.9 ± 6.6 比 25.5 ± 7.07)、逻辑器官功能障碍评分(5.6 ± 3.2 比 6.3 ± 3.6)和序贯器官衰竭评估(SOFA)评分在第 1 天显著降低(8 ± 3.5 比 9.6 ± 3.7;<.01)。感染的主要来源是腹腔内(32.5%),尽管 56.7%的病例可以进行微生物分离。2011 年队列的 48 小时(7%比 14.8%)、ICU(27.2%比 48.2%)和住院(36.7%比 54.3%)死亡率明显降低。与死亡相关的最主要因素是 APACHE II 评分、年龄、既往免疫抑制和肝功能不全、酒精中毒、医院感染和 SOFA 评分变化。
尽管脓毒症/脓毒性休克的发病率在 10 年内保持不变,但 SSC 指南的实施导致总体死亡率显著下降。入住 ICU 时患者的严重程度降低和早期死亡率降低表明早期诊断、更好的初始管理和更早的抗生素治疗得到了改善。